Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemia, karvainen solu - antineoplastiset aineet - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rintojen kasvaimet - antineoplastiset aineet - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Finlanda - finlandeză - Ecolab

ecolab deutschland gmbh -

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kana - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetyylifumaraatti - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomidi - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit, selektiiviset immunosuppressantit - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiset aineet - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - hengitystyön syntiusvirusinfektiot - rokotteet - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. katso kohdat 4. 2 ja 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. käyttö tämä rokote tulee virallisten suositusten mukaisesti.